Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125

Journal of the National Cancer Institute

Volumn 99, Issue 22, 2007, Pages 1706-1714

  Van Calster, Ben ^a   Timmerman, Dirk ^b   Bourne, Tom ^c   Testa, Antonia Carla ^d   Van Holsbeke, Caroline ^b   Domali, Ekaterini ^b   Jurkovic, Davor ^e   Neven, Patrick ^b   Van Huffel, Sabine ^a   Valentin, Lil ^f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d CATHOLIC UNIVERSITY   (Italy)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ABSCESS; ADNEXA DISEASE; ADNEXAL MASS; ADULT; ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; ENDOMETRIUM TUMOR; FEMALE; FIBROMA; GRAY SCALE ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR CLASSIFICATION; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DOPPLER FLOWMETRY; EUROPE; GYNECOLOGY; IMMUNOLOGY; MANPOWER; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATTERN RECOGNITION; POSTMENOPAUSE; PREDICTION AND FORECASTING; PREMENOPAUSE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE TUBE TUMOR; VAGINA;

ADNEXAL DISEASES; ADULT; AGED; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; EUROPE; FALLOPIAN TUBE NEOPLASMS; FEMALE; GYNECOLOGY; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PATTERN RECOGNITION, VISUAL; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; PROSPECTIVE STUDIES; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER; VAGINA;

EID: 38449099099     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm199     Document Type: Article

References (48)

1. Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355-8.
2. Royal College of Obstetricians and Gynaecologists. Guideline no. 34. Ovarian cysts in postmenopausal women. London: RCOG press; 2003.
3. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, et al. Prognostic importance of preoperative CA 125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol 2005;23:5938-42.
4. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
5. Bon GG, Kenemans P, Verstraeten R, van Kamp GJ, Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 1996;174:107-14.
6. Gadducci A, Baicchi U, Marai R, Ferdeghini M, Bianchi R, Facchini V. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996;60:197-202.
7. Predanic M, Vlahos N, Pennisi JA, Moukhtar M, Aleem FA. Color and pulsed Doppler sonography, gray-scale imaging, and serum CA 125 in the assessment of adnexal disease. Obstet Gynecol 1996;88:283-8.
8. Eltabbakh GH, Belinson JL, Kennedy AW, Gupta M, Webster K, Blumenson LE. Serum CA-125 measurements > 65 U/ml. clinical value. J Reprod Med 1998;43:635-6.
9. Tuxen MK. Tumor marker CA125 in ovarian cancer. J Tumor Marker Oncol 2001;16:49-68.
10. Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B, Zurawski VR Jr. Preoperative evaluation of serum CA125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986;67:414-6.
11. Tamakoshi K, Kikkawa F, Shibata K, Tomoda K, Obata NH, Wakahara F. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol 1996;62:67-72.
12. Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol 2000;78:16-20.
13. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.
14. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988;71:751-6.
15. Buamah PK, Skillen AW. Serum CA 125 concentrations in patients with benign ovarian tumours. J Surg Oncol 1994;56:71-4.
16. Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 1989;35:139-44.
17. Bourne T, Campbell S, Steer C, Whitehead MI, Collins WP. Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. Br Med J 1989;299:1367-70.
18. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
19. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170:81-5.
20. Timmerman D. The use of mathematical models to evaluate pelvic masses; can they beat an expert operator? Best Pract Res Clin Obstet Gynaecol 2004;18:91-104.
21. Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol 2004;18:105-23.
22. de Kroon CD, van der Sandt HA, van Houwelingen JC, Jansen FW. Sonographic assessment of non-malignant ovarian cysts: does sonohistology exist? Hum Reprod 2004;19:2138-43.
23. Timmerman D, Schwärzler P, Collins WP, Claerhout F, Coenen M, Amant F. Subjective assessment of adnexal masses using ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999;13:11-6.
24. Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999;14:338-47.
25. Jermy K, Luise C, Bourne T. The characterization of common ovarian cysts in premenopausal women. Ultrasound Obstet Gynecol 2001;17:140-4.
26. Valentin L, Hagen B, Tingulstad S, Eik-Nes S. Comparison of "pattern recognition" and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 2001;18:357-65.
27. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 2005;23:8794-801.
28. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I. Terms, definitions and measurements to describe the ultrasonographic features of adnexal tumors: a consensus opinion from the international ovarian tumor analysis (IOTA) group. Ultrasound Obstet Gynecol 2000;6:500-5.
29. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993;39:2509-13.
30. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary, in 25th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2003;83:S135-7.
31. Newcombe RG. Two-sided confidence intervals for the single proportion comparison of seven methods. Stat Med 1998;17:857-72.
32. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998;17:2635-50.
33. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998;17:873-90.
34. Newcombe RG. Confidence intervals for an effect size measure based on the Mann-Whitney statistic: Part 2: asymptotic methods and evaluation. Stat Med 2006;25:559-73.
35. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on tumor markers guidelines for clinical use. Int J Gynecol Cancer 2005;15:679-91.
36. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21:215-45.
37. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 2002;100:59-64.
38. Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B, Kopolovic J, et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol 2000;83:541-6.
39. Makar AP, Kaern J, Kristensen GB, Vergote I, Bormer OP, Trope CG. Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary. Int J Gynecol Cancer 1993;3:299-303.
40. Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp RC, et al. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol 1992;46:226-9.
41. Somigliana E, Vigano P, Tirelli AS, Felicetta I, Torresani E, Vignali M, et al. Use of the concomitant serum dosage of CA 125, CA 19-9 and interleukin-6 to detect the presence of endometriosis. Results from a series of reproductive age women undergoing laparoscopic surgery for benign gynaecological conditions. Hum Reprod 2004;19:1871-6.
42. Kitawaki J, Ishihara H, Koshiba H, Kiyomizu M, Teramoto M, Kitaoka Y, et al. Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum Reprod 2005;20:1999-2003.
43. Phupong V, Chen O, Ultchaswadi P. High level of CA 125 due to large endometrioma. J Med Assoc Thai 2004;87:1108-11.
44. Cane PA, Colleen-Lopez E, Platt LD, Karlan BY. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening. Gynecol Oncol 1995;57:240-5.
45. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6.
46. Timmerman D, Van Calster B, Jurkovic D, Valentin L, Testa AC, Bernard JP, et al. The inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol 2007;25:4194-200.
47. Bonfrer J, Baan A, Jansen E, Lentfer D, Kenemans P. Technical evaluation of three second generation CA 125 assays. Eur J Clin Chem Clin Biochem 1994;32:201-7.
48. Davelaar E, van Kamp G, Verstraeten R, Kenemans P. Comparison of seven immunoassays for the quantifi cation of CA 125 antigen in serum. Clin Chem 1198;44:1417-22.